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Abstract
Brodifacoum is a highly potent and long-acting anticoagulant rodenticide (LAAR). LAAR poisoning possibly leads to
long term bleeding problems and needs vitamin K1 treatment for several months. Due to economic concern, tablet
preparation of vitamin K1 was not available in most of the countries, including Taiwan. In literature, few reports had
pointed out that injectable form of vitamin K could be used orally in patients on anticoagulant therapy with supratherapeutic state. Here, we reported a family with 3 members suffering from brodifacoum poisoning with severe coagulopathy needed to prolong hospitalization for intravenous vitamin K1 therapy, and successfully managed with
injectable formula orally for about 5 months. Oral administration of injectable vitamin K1 might be a suitable substitute
for intravenous route in long-term treatment for LAAR poisonings.
Keywords: Brodifacoum, Rodenticide, Oral administration, Vitamin K1

1. Introduction

A

nticoagulant compounds are the most common used rodenticides in the world.
Warfarin had been introduced for rodenticide use in
the 1940s, and gradually replaced by “superwarfarins” due to the emergence of warfarin-resistant rats. Superwarfarins are highly potent vitamin
K antagonists, as nominated due to being much
more potent and long acting than warfarin, so called
long-acting anticoagulant rodenticide (LAAR).
Common examples of LAAR include brodifacoum,
bromadiolone, and chlorophacinone. Long-acting
anticoagulant rodenticides have an extremely high
afﬁnity for vitamin K epoxide reductase (VKOR), a
key enzyme in liver for vitamin K reactivation,
compared with warfarin, characterized by rebound
coagulopathy and bleeding after initial treatment
and the need for high-dose, long-term therapy of
vitamin K [1].
Exposure to these rodenticides, mostly by oral
route, can result in potentially fatal hemorrhage.
Therefore, a prolonged prothrombin time as indicated with elevated international normalized ratio

(INR) caused by LAAR intoxication warrants
vitamin K1 treatment. The tissue half-lives of
LAARs estimated at the range of 16 to 220days, and
vitamin K1 administration is usually needed for
extended periods of time, ranging from 28 to 730
days in the maintenance phase of treatment [1e3].
Vitamin K1 is fat-soluble and preferred being used
intravenously in the newborns for bleeding tendency prevention, also in cases of supra-therapeutic
state of anticoagulant and in LAAR poisonings.
Oral vitamin K to reverse the coagulopathy
induced by warfarin and LLARs is being effective
and promising. But, the rising cost of vitamin K
tablet formulation had resulted it to be unavailable
in most of the countries due to economic concern,
including Taiwan [1]. Oral administration of the less
expensive injectable vitamin K1 has been suggested
in the newborns or in supra-therapeutic state of
anticoagulant therapy [4,5]. The compounded oral
solution showed increased bioavailability as
compared with the tablet formulation. In addition,
oral vitamin K solution has been shown to have
efﬁcacy similar to oral tablets relative to the reversal
of vitamin K antagonists for patients with an
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elevated INR [6]. In an outbreak of patients
poisoned with long-acting anticoagulant rodenticide-tainted synthetic cannabinoids (LAAR-SC) in
2018, oral administration of injectable vitamin K1
had been suggested due to shortage of oral form of
vitamin K1 [7]. Here, we reported a family with 3
members suffered from brodifacoum poisoning
with severe coagulopathy needed for prolong hospitalization and intravenous vitamin K1 therapy. We
prescribed injectable vitamin K1 formula orally
substituted intravenously for them after restoring
their coagulation ability and can follow-up successfully on outpatient service.

2. Case report
A 45-year-old mother (65 KG-BW) brought her
two sons (age 18 and 15) to our emergency department with chief complaints of epistaxis and hematuria for 2e3 days. The mother confessed that she
blended 500 mL of Brodifacoum solution (0.005% w/
w) into the fried rice and fruit juice, and shared in
dinner about 10 days before their visit. The mother
suffered from hematuria and epistaxis. The elder
son (82 KG-BW), a case of poliomyelitis history and
ambulatory with self-controlled wheelchair, developed mild fever, left ﬂank pain and hematuria. The
second son (74 KG-BW) suffered from epistasis,
gum bleeding, abdominal pain, and tarry stool.
Their initial prothrombin times/INRs all were
greater than the maximal measurable value (>81 s/
9.6), and prolongation of activated partial thromboplastin times (aPTT) were also noted.
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After fresh frozen plasma transfusion and vitamin
K1 intravenous injection, they were admitted for
more doses of vitamin K1. No more bleeding tendency with normal or near normal INR were noted
under 30 mg to 40 mg of vitamin K1 treatment in 3
days. But, rebounding of INR and prolonged hospitalization were noted if we tried to taper the dose
of vitamin K1 (Fig. 1). We started to try oral
administration of injectable vitamin K1 preparation
50 mg to 60 mg daily later and adjusted the dose by
serial INR examinations in the outpatient department. The undiluted vitamin K1 preparation is
10 mg/mL stored in a light-proof sterilized glass
bottle and refrigerator. We prepared the fresh
compounds every two weeks. They reported
absence of adverse effects, except for the unpleasant
taste of the oily ﬂuid. After 145 days of oral vitamin
K1 therapy, they recovered with normal INR and
needed no more medication again.

3. Discussion
These 3 patients presented typical presentations
about 2 weeks after LAAR large dose exposure.
Their blood tests of PT, aPTT and INR returned to
normal and no more bleeding tendency shortly after
fresh frozen plasma transfusion and vitamin K1
prescription. In animal studies, the serum half-life
of vitamin K1 is about 6 h, and in human studies, the
vitamin K dependent coagulation factors in blood
are to rise at 6 to 8 h after therapy [7]. Most of the
LAARs are highly lipid soluble and increased afﬁnity to hepatic tissue and hepatic enzymes, making

Fig. 1. Serial INR and doses of vitamin K1 of the 15 y/o boy. He initially presented epistasis, gum bleeding, abdominal pain, and tarry stool. Poor
compliance was noted between days 63 and 77. IV: intravenous route; PO: oral route.

them to be 100 times more potent and longer acting
than warfarin. The great disparate half-lives of
vitamin K1 and LAARs makes it possible that
recurrent symptoms or abnormalities in coagulation
assays develop in 12 to 16 h after initial treatment.
Thus, chronic maintenance therapy with vitamin K1
should be promptly initiated and may be required
for several months [1]. So, the doses of vitamin K1 to
keep normal INRs for these patients were initially
titrated to 30 mg to 40 mg/day in divided doses.
Vitamin K1 can be administered through oral,
intramuscular, subcutaneous, and intravenous
routes; no comparing studies of the different efﬁcacy
on LAAR poisoning in literature. On the other hand,
in warfarin reversal study, Intravenous administration could correct more quickly than oral route
within 6 to 12 h, instead of 24 h [1]. However, potential anaphylactoid reaction with intravenous
administration and hematoma formation with
intramuscular injection of oily vitamin K1 in LAAR
poisoning were concerned frequently. In addition,
the tablet formulation of vitamin K1 is difﬁcult to
obtain or unavailable due to the increased production cost in many countries, also in Taiwan. One
option to resolve these problems for patient care
might be using a less expensive formulation of
injectable vitamin K1 as an alternative for LAARs
poisoning.
In literature, oral administration of injectable
vitamin K1 has been shown to be effective and safe
[4,5]. Crowther and colleagues found that administering injectable vitamin K1 orally might be more
effective than subcutaneous vitamin K1 for INR
reversing in patients under warfarin therapy with
INRs between 4.5 and 10 [4]. In healthy volunteer
trial, Van Rein et al. discovered the bioavailability of
5-mg Vitamin K1 solution was greater than that of
tablet form. They also found that vitamin K1 oil
solutions decreased slightly more INR than tablets
in patients on anticoagulant therapy with an INR of
7.0e11.0 [5]. The stability of injectable vitamin K1
solution for oral purpose has also been studied. In
literature review by Afanasjeva [6], several preparations have been mentioned; including undiluted
injectable vitamin K or compounded oral solution.
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He found that the ﬂuid's preparation stability ranges
from 30 days to 111 days under both room and
refrigerated temperatures when protected from
light. The unpleasant taste of undiluted vitamin K1
can be eliminated when mixed with orange juice.

4. Conclusion
While tablet formula or preparation of vitamin k1
is generally not accessible, oral administration of
injectable vitamin K1 appears to be an effective and
safe way for maintaining long-term therapy of
LAARs poisoning in out-patient clinics to keep
suitable INR. More investigations are needed to
clarify the pharmacokinetics of injectable vitamin
K1 from oral route and its effect on toxicology of
LAARs.
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